The Efficacy and Safety of Nicorandil for Periprocedural Myocardial Injury in Patients Undergoing PCI: A Meta-Analysis

Table 1

Characteristics of studies included in the meta-analysis.

Authors	Year	Country	Sample size		Male, no. (%)		Average age (years)
			E	C	E	C	E	C
Ono et al. [29]	2004	Japan	33	25	22 (66.7)	16 (64.0)	64 ± 13	66 ± 12
Ishii et al. [23]	2005	Japan	185	183	144 (77.8)	154 (84.1)	63 ± 9.4	64 ± 10.1
J. Kim et al. [24]	2005	Korea	42	54	27 (64.3)	32 (59.3)	60.4 ± 11.7	61.7 ± 8.2
Murakami et al. [27]	2006	Japan	91	101	75 (82.4)	81 (80.2)	65.0 ± 9.7	66.1 ± 10.3
S. Kim et al. [25]	2012	Korea	54	55	36 (70.4)	46 (83.6)	65.5 ± 7.4	63.2 ± 9.2
Hwang et al. [22]	2013	Korea	41	40	20 (48.8)	25 (62.5)	66.2 ± 9	65.3 ± 10
Hirohata et al. [21]	2014	Japan	33	29	25 (75.8)	20 (69.0)	73 ± 13	68 ± 9
Yang et al. a [31]	2014	China	45	47	31	31	NA	NA

PMI = periprocedural myocardial injury, MACE = major adverse cardiovascular events, and PCI = percutaneous coronary intervention.